Long-term effects of high-dose zidovudine treatment on neuropsychological performance in mildly symptomatic HIV-positive patients: Results of a randomized, double-blind, placebo-controlled investigation

Antolin Llorente, Wilfred G. Van Gorp, Martin J. Stern, Lance George, Paul Satz, Thomas D. Marcotte, Gilbert M. Calvillo, Charles H. Hinkin

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

This study examined the treatment outcome of high-dose (1500 mg/day) zidovudine (AZT) on neuropsychological (NP) functioning (Trailmaking Test A & B, WAIS-R Digit Symbol, and Rey Auditory Verbal Learning Test) across a 12-month period in mildly symptomatic HIV-1 seropositive men (n = 46 at entry) enrolled in a randomized, double-blind, placebo-controlled trial (VA Cooperative Studies Program #298). Neither short-term (0-6 months) nor long-term (0-12 months) AZT administration revealed enhancement in NP performance. The results suggest that, although AZT may afford patients prophylactic benefits, protracted high-dose AZT treatment does not improve NP functioning in mildly symptomatic HIV-positive individuals.

Original languageEnglish (US)
Pages (from-to)27-32
Number of pages6
JournalJournal of the International Neuropsychological Society
Volume7
Issue number1
DOIs
StatePublished - Mar 10 2001

Fingerprint

Verbal Learning
Zidovudine
HIV-1
Placebos
HIV
Therapeutics

All Science Journal Classification (ASJC) codes

  • Clinical Neurology
  • Psychiatry and Mental health
  • Neuroscience(all)
  • Neurology
  • Psychology(all)

Cite this

@article{225a5f5a2569449db543124c7461f327,
title = "Long-term effects of high-dose zidovudine treatment on neuropsychological performance in mildly symptomatic HIV-positive patients: Results of a randomized, double-blind, placebo-controlled investigation",
abstract = "This study examined the treatment outcome of high-dose (1500 mg/day) zidovudine (AZT) on neuropsychological (NP) functioning (Trailmaking Test A & B, WAIS-R Digit Symbol, and Rey Auditory Verbal Learning Test) across a 12-month period in mildly symptomatic HIV-1 seropositive men (n = 46 at entry) enrolled in a randomized, double-blind, placebo-controlled trial (VA Cooperative Studies Program #298). Neither short-term (0-6 months) nor long-term (0-12 months) AZT administration revealed enhancement in NP performance. The results suggest that, although AZT may afford patients prophylactic benefits, protracted high-dose AZT treatment does not improve NP functioning in mildly symptomatic HIV-positive individuals.",
author = "Antolin Llorente and {Van Gorp}, {Wilfred G.} and Stern, {Martin J.} and Lance George and Paul Satz and Marcotte, {Thomas D.} and Calvillo, {Gilbert M.} and Hinkin, {Charles H.}",
year = "2001",
month = "3",
day = "10",
doi = "10.1017/S1355617701711034",
language = "English (US)",
volume = "7",
pages = "27--32",
journal = "Journal of the International Neuropsychological Society",
issn = "1355-6177",
publisher = "Cambridge University Press",
number = "1",

}

Long-term effects of high-dose zidovudine treatment on neuropsychological performance in mildly symptomatic HIV-positive patients : Results of a randomized, double-blind, placebo-controlled investigation. / Llorente, Antolin; Van Gorp, Wilfred G.; Stern, Martin J.; George, Lance; Satz, Paul; Marcotte, Thomas D.; Calvillo, Gilbert M.; Hinkin, Charles H.

In: Journal of the International Neuropsychological Society, Vol. 7, No. 1, 10.03.2001, p. 27-32.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Long-term effects of high-dose zidovudine treatment on neuropsychological performance in mildly symptomatic HIV-positive patients

T2 - Results of a randomized, double-blind, placebo-controlled investigation

AU - Llorente, Antolin

AU - Van Gorp, Wilfred G.

AU - Stern, Martin J.

AU - George, Lance

AU - Satz, Paul

AU - Marcotte, Thomas D.

AU - Calvillo, Gilbert M.

AU - Hinkin, Charles H.

PY - 2001/3/10

Y1 - 2001/3/10

N2 - This study examined the treatment outcome of high-dose (1500 mg/day) zidovudine (AZT) on neuropsychological (NP) functioning (Trailmaking Test A & B, WAIS-R Digit Symbol, and Rey Auditory Verbal Learning Test) across a 12-month period in mildly symptomatic HIV-1 seropositive men (n = 46 at entry) enrolled in a randomized, double-blind, placebo-controlled trial (VA Cooperative Studies Program #298). Neither short-term (0-6 months) nor long-term (0-12 months) AZT administration revealed enhancement in NP performance. The results suggest that, although AZT may afford patients prophylactic benefits, protracted high-dose AZT treatment does not improve NP functioning in mildly symptomatic HIV-positive individuals.

AB - This study examined the treatment outcome of high-dose (1500 mg/day) zidovudine (AZT) on neuropsychological (NP) functioning (Trailmaking Test A & B, WAIS-R Digit Symbol, and Rey Auditory Verbal Learning Test) across a 12-month period in mildly symptomatic HIV-1 seropositive men (n = 46 at entry) enrolled in a randomized, double-blind, placebo-controlled trial (VA Cooperative Studies Program #298). Neither short-term (0-6 months) nor long-term (0-12 months) AZT administration revealed enhancement in NP performance. The results suggest that, although AZT may afford patients prophylactic benefits, protracted high-dose AZT treatment does not improve NP functioning in mildly symptomatic HIV-positive individuals.

UR - http://www.scopus.com/inward/record.url?scp=0035112508&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0035112508&partnerID=8YFLogxK

U2 - 10.1017/S1355617701711034

DO - 10.1017/S1355617701711034

M3 - Article

C2 - 11253839

AN - SCOPUS:0035112508

VL - 7

SP - 27

EP - 32

JO - Journal of the International Neuropsychological Society

JF - Journal of the International Neuropsychological Society

SN - 1355-6177

IS - 1

ER -